Categories

Volume 4 Issue 2 (March - April, 2016)

Original Articles

A comparative study of Enoxaparin and fondaparinux in unstable coronary artery disease
Pratik Kumar Soni

Background: Coronary heart disease is the leading cause of death in the US general population. With the obesity pandemic and the expected worsening of cardiovascular risk factors in the general population, the incidence and the prevalence of heart disease is expected to rise. The present study compared Enoxaparin and fondaparinux in unstable coronary artery disease. Materials & Methods: 82 patients of unstable angina of both genders were divided into 2 groups of 41 each. Group I patients were given Enoxaparin in the dose of 1 mg/kg body weight, subcutaneously, twice daily and group II was given Fondaparinux in a dose of 2.5 mg/kg body weight, once daily, subcutaneously. In both groups, risk factors and treatment outcome was compared. Results: Group I had 30 males and 11 females and group II had 28 males and 13 females. Common risk factors were smoking in 24 in group I and 23 in group II, diabetes in 30 in group I and 36 in group II, hypertension in 22 in group I and 26 in group II, family history 10 in group I and 7 in group II and >2 factors 15 in group I and 11 in group II. The recovery was seen in 36 at day 9 and 39 at day 30 in group I and 38 in group I at day 9 and 40 at day 30 in group II, recurrent MI was seen in 2 at day 9 in group I and 2 and 1 at fay 9 and day 30 in group II, hemorrhage was seen in 3 and 2 at day 9 and day 30 in group I and 1 at day 9 in group II. No mortality was reported in either of the group. The difference was non- significant (P>0.05). Conclusion: Both drugs were comparable in treatment outcome in patients with unstable angina. Key words: Enoxaparin, Fondaparinux, Unstable angina.

 
Html View | Download PDF | Current Issue